
price close busi septemb
global leader diagnost breast
imag surgic product focu women
diagnost tool
bolt-on could new trend focal
therapeut add breast health leadership
announc close today acquisit second
acquisit breast surgeri past month upon deal close expect earli
octob give fda-clear product expand suit
breast health surgic product complement leadership breast imag
estim focal add revenu recal recent
acquisit faxiton expect add nearli combin next year
two bolt-on long-believ industry-lead product
breast health diagnost encourag see compani acquir
asset help acceler top line gross margin help achiev
aspir revenu goal mid singl digit growth reiter hold rais
pt updat model time
deal sign agreement acquir privately-held focal therapeut
cash manufactur implant devic
breast tumor mark second acquisit area breast surgeri
sinc end juli recal acquir faxitron bioptic juli faxitron
market broad portfolio product across major categori includ digit specimen
radiographi breast lesion local sentinel lymph node biopsi
number focal deal expect close octob impli
multipl trail revenu doubl
trail multipl paid acquir faxitron deal indic
transact accret revenu growth rate estim
neutral holx non-gaap ep accret thereaft conced
trail multipl premium multipl think focal may well
double-digit grower thu hypothet could look like rev
think
product- biozorb manufactur biozorb marker
implant devic mark surgic site tissu remov three dimens
marker consist open framework structur slowli resorb bodi
time six titanium marker clip stay perman help mark sight
tumor resect purpos follow-up imag biozorb place time
surgic tissu remov exampl breast surgeri open design allow
tissu in-growth heal process brief help video biozorb use
practic found
view best point follow poor earli integr
cynosur acquisit applaud bolt-on deal acceler top line
growth particularli accret gm stay sidelin await greater
evid better top line growth improv margin either recoveri
exit cynosur pt use multipl adj ep
share nearli ytd averag compani return
coverag ytd expect provid guidanc upcom
earn call time expect initi estim
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price septemb
diagnost tool
hold unchang target price septemb
diagnost tool
